Revenue rose only 0.8 percent as the healthcare division saw its sales drop 2.3 percent to euro4.2 million due to reforms in various countries.
The crop science division fared better with revenues up 3.1 percent. The material science unit also saw sales rise 3.5 percent.
Bayer CEO Marijn Dekkers said the company's outlook for 2011 remained on track following "significant progress" with products from the research and development pipeline.